Floatz logo

Pexidartinib

Glioblastoma

Daiichi SankyoSmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

342 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB
Camustine
Leland Metheny
Phase 3BB
(+)-Vincristine
University of Cincinnati
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Pexidartinib is also rated in:

melanomaDormant
CCC
Indicative · Phase 2
55 / 100
View asset →
angiosarcomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
gastrointestinal stromal tumorDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →